Leroi R
Helv Chir Acta. 1977 Jun;44(3):403-14.
From a selection of 547 patients with mamma carcinoma stages I and II it is statistically shown that the 5- and 10-year survival rates are significantly improved with postoperative use of Iscador (Viscum album); this in comparison with the conventional treatment on its own. No toxic side effects have been experienced.
从547例I期和II期乳腺癌患者的样本中经统计学分析表明，与单纯的传统治疗相比，术后使用Iscador（欧洲红豆杉）可显著提高5年和10年生存率。且未观察到毒副作用。
